Key clinical point: Financial savings affect the rate of adoption of biosimilars.
Major finding: Costs for reference and the biosimilar infliximab-abda (Renflexis) were similar for an academic medical center, but the cost of the biosimilar was $507.90 lower than that for the reference product at a neighboring Veterans Affairs Medical Center.
Study details: A cross-sectional study of medical record data for the University of Pennsylvania Health System and the local Veterans Affairs Medical Center.
Disclosures: The study was funded by grants from the Department of Veterans Affairs, the National Institutes of Health, and the American Diabetes Association. Dr. Baker has received fees from Bristol Myers Squibb and Gilead, and another author reported receiving research support paid to his institution by Pfizer and UCB, as well as receiving consulting fees from nine pharmaceutical companies.
Baker JF et al. Arthritis Rheumatol. 2020 Apr 6. doi: 10.1002/art.41277.